Agenus shareholders have suffered a modest ~13% loss since my last analysis, based on cash flow challenges and lack of near term catalysts. I examine the Q2/2025 earnings release and 10-Q to assess ...

CEO Garo Armen highlighted new BOT/BAL data validating durable responses in historically untreatable cold tumors, emphasizing, "we're talking about new data and more mature data." He announced a ...

I remain cautiously optimistic about Agenus, driven by BOT/BAL's strong clinical data and cost-reduction efforts, but maintain a speculative 2/5 conviction rating. The BOT/BAL program shows promising ...